医学
内科学
长春新碱
美罗华
依托泊苷
置信区间
强的松
相伴的
环磷酰胺
胃肠病学
国际预后指标
无进展生存期
淋巴瘤
弥漫性大B细胞淋巴瘤
化疗
单变量分析
外科
多元分析
作者
Birte Friedrichs,Maike Nickelsen,Marita Ziepert,Bettina Altmann,Mathias Haenel,Andreas Viardot,Christian Schmidt,Christian Ruebe,Markus Loeffler,Michael G. Pfreundschuh,Andreas Rosenwald,Bertram Glaß,Georg Lenz,Norbert Schmitz,for the German high‐grade lymphoma Study Group
摘要
Summary To further improve outcome in young high‐risk patients with diffuse large B‐cell lymphoma (DLBCL) the number of rituximab (R) infusions was doubled in combination with standard CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone) chemotherapy. Seventy‐seven patients (aged 18–60 years) with an age‐adjusted International Prognostic Index of 2–3 received 12 × R (375 mg/m2) on days 0, 1, 4, 8, 15, 22, 29, 43, 57, 71, 85 and 99 together with eight cycles of CHOEP‐14. Results were retrospectively compared to those of patients receiving 6 × R and 8 × CHOEP‐14 in the standard arm of the randomized R‐MegaCHOEP trial. Two‐year overall survival (OS) was 82% [95% confidence interval (CI) 73%–92%]; 2‐year event‐free (EFS) and progression‐free survival (PFS) was 69% (95% CI 59–80%) and 76% (95% CI 66%‐–6%), respectively. Comparing 12 to six doses of R revealed no differences (univariate/multivariate) in EFS (at 2 years: 69% vs. 71%), PFS (76% vs. 75%) and OS (82% vs. 85%), with P = 0·766, P = 0·871 and P = 0·843, respectively. Doubling the number of R infusions concomitant to CHOEP did not improve treatment outcomes. Nonetheless, OS and PFS of young high‐risk patients who received only six infusions of R combined with CHOEP remain excellent and were confirmed in an independent cohort of patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI